Gastric cancer is one of the most common malignant tumours worldwide, with a high degree of malignancy and a poor prognosis. While early gastric cancer can be cured by surgical treatment, locally advanced gastric cancer requires neoadjuvant therapy to shrink the tumour, suppress potential metastases, achieve down-staging, and provide patients with the opportunity for radical surgery to prolong their survival. This article reviews the current status and progress of neoadjuvant chemotherapy for locally advanced gastric cancer.
References
[1]
Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660
[2]
GBD 2017 Stomach Cancer Collaborators (2020) The Global, Regional, and National Burden of Stomach Cancer in 195 Countries, 1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterology Hepatology, 5, 42-54.
[3]
Zhao, J.K., Wu, M., Kim, C.H., Jin, Z.Y., Zhou, J.Y., Han, R.Q., et al. (2017) Jiangsu Four Cancers Study: A Large Case-Control Study of Lung, Liver, Stomach, and Esophageal Cancers in Jiangsu Province, China. European Journal of Cancer Prevention, 26, 357-364. https://doi.org/10.1097/CEJ.0000000000000262
[4]
Johnston, F.M. and Beckman, M. (2019) Updates on Management of Gastric Cancer. Current Oncology Reports, 21, Article No. 67. https://doi.org/10.1007/s11912-019-0820-4
[5]
Ajani, J.A., Bentrem, D.J., Besh, S., D’Amico, T.A., Das, P., Denlinger, C., et al. (2013) Gastric Cancer, Version 2.2013: Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network, 11, 531-546.
[6]
Smyth, E.C., Nilsson, M., Grabsch, H.I., van Grieken, N.C. and Lordick, F. (2020) Gastric Cancer. The Lancet, 396, 635-648. https://doi.org/10.1016/S0140-6736(20)31288-5
[7]
Grizzi, G., Petrelli, F., Di Bartolomeo, M., Viti, M., Moraes, T.M., Luciani, A., et al. (2022) Preferred Neoadjuvant Therapy for Gastric and Gastroesophageal Junction Adenocarcinoma: A Systematic Review and Network Meta-Analysis. Gastric Cancer, 25, 982-987. https://doi.org/10.1007/s10120-022-01314-9
[8]
Cai, Z.L., Yin, Y., Shen, C.Y., Wang, J., Yin, X.N., Chen, Z.X., et al. (2018) Comparative Effectiveness of Preoperative, Postoperative and Perioperative Treatments for Resectable Gastric Cancer: A Network Meta-Analysis of the Literature from the Past 20 Years. Surgical Oncology, 27, 563-574. https://doi.org/10.1016/j.suronc.2018.07.011
[9]
Alsina, M., Miquel, J.M., Diez, M., Castro, S. and Tabernero, J. (2019) How I Treat Gastric Adenocarcinoma. ESMO Open, 4, e000521. https://doi.org/10.1136/esmoopen-2019-000521
[10]
Macdonald, J.S., Smalley, S.R., Benedetti, J., Hundahl, S.A., Estes, N.C., Stemmermann, G.N., et al. (2001) Chemoradiotherapy after Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal Junction. The New England Journal of Medicine, 345, 725-730. https://doi.org/10.1056/NEJMoa010187
[11]
Sasako, M., Sakuramoto, S., Katai, H., Kinoshita, T., Furukawa, H., Yamaguchi, T.,et al. (2011) Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy with S-1 versus Surgery Alone in Stage II or III Gastric Cancer. Journal of Clinical Oncology, 29, 4387-4393. https://doi.org/10.1200/JCO.2011.36.5908
[12]
Noh, S.H., Park, S.R., Yang, H.K., Chung, H.C., Chung, I.J., Kim, S.W., et al. (2014) Adjuvant Capecitabine plus Oxaliplatin for Gastric Cancer after D2 Gastrectomy (CLASSIC): 5-Year Follow-Up of an Open-Label, Randomised Phase 3 Trial. The Lancet Oncology, 15, 1389-1396. https://doi.org/10.1016/S1470-2045(14)70473-5
[13]
Songun, I., Putter, H., Kranenbarg, E.M., Sasako, M. and van de Velde, C.J. (2010) Surgical Treatment of Gastric Cancer: 15-Year Follow-Up Results of the Randomised Nationwide Dutch D1D2 Trial. The Lancet Oncology, 11, 439-449. https://doi.org/10.1016/S1470-2045(10)70070-X
[14]
Yoshikawa, T., Terashima, M., Mizusawa, J., Nunobe, S., Nishida, Y., Yamada, T., et al. (2019) Four Courses versus Eight Courses of Adjuvant S-1 for Patients with Stage II Gastric Cancer (JCOG1104 [OPAS-1]): An Open-Label, Phase 3, Non-Inferiority, Randomised Trial. The Lancet Gastroenterology and Hepatology, 4, 208-216. https://doi.org/10.1016/S2468-1253(18)30383-2
[15]
Yoshida, K., Kodera, Y., Kochi, M., Ichikawa, W., Kakeji, Y., Sano, T., et al. (2019) Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial. Journal of Clinical Oncology, 37, 1296-1304. https://doi.org/10.1200/JCO.18.01138
[16]
Park, S.H., Lim, D.H., Sohn, T.S., Lee, J., Zang, D.Y., Kim, S.T., et al. (2021) A Randomized Phase III Trial Comparing Adjuvant Single-Agent S1, S-1 with Oxaliplatin, and Postoperative Chemoradiation with S-1 and Oxaliplatin in Patients with Node-Positive Gastric Cancer after D2 Resection: The ARTIST 2 Trial. Annals of Oncology, 32, 368-374. https://doi.org/10.1016/j.annonc.2020.11.017
[17]
Japanese Gastric Cancer Association (2023) Japanese Gastric Cancer Treatment Guidelines 2021 (6th Edition). Gastric Cancer, 26, 1-25. https://doi.org/10.1007/s10120-022-01331-8
[18]
Zhang, X., Liang, H., Li, Z., Xue, Y., Wang, Y., Zhou, Z., et al. (2021) Perioperative or Postoperative Adjuvant Oxaliplatin with S-1 versus Adjuvant Oxaliplatin with Capecitabine in Patients with Locally Advanced Gastric or Gastro-Oesophageal Junction Adenocarcinoma Undergoing D2 Gastrectomy (RESOLVE): An Open-Label, Superiority and Non-Inferiority, Phase 3 Randomised Controlled Trial. The Lancet Oncology, 22, 1081-1092. https://doi.org/10.1016/S1470-2045(21)00297-7
[19]
Wilke, H., Preusser, P., Fink, U., Gunzer, U., Meyer, H.J., Meyer, J., et al. (1989) Preoperative Chemotherapy in Locally Advanced and Nonresectable Gastric Cancer: A Phase II Study with Etoposide, Doxorubicin, and Cisplatin. Journal of Clinical Oncology, 7, 1318-1326. https://doi.org/10.1200/JCO.1989.7.9.1318
[20]
Cunningham, D., Allum, W.H., Stenning, S.P., Thompson, J.N., van de Velde, C.J., Nicolson, M., et al. (2006) Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer. The New England Journal of Medicine, 355, 11-20. https://doi.org/10.1056/NEJMoa055531
[21]
Ychou, M., Boige, V., Pignon, J.P., Conroy, T., Bouché, O., Lebreton, G., et al. (2011) Perioperative Chemotherapy Compared with Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial. Journal of Clinical Oncology, 29, 1715-1721. https://doi.org/10.1200/JCO.2010.33.0597
[22]
Ajani, J.A., Barthel, J.S., Bekaii-Saab, T., Bentrem, D.J., D’Amico, T.A., Das, P., et al. (2010) Gastric Cancer. Journal of the National Comprehensive Cancer Network, 8, 378-409. https://doi.org/10.6004/jnccn.2010.0030
[23]
Al-Batran, S.E., Homann, N., Pauligk, C., Goetze, T.O., Meiler, J., Kasper, S., et al. (2019) Perioperative Chemotherapy with Fluorouracil plus Leucovorin, Oxaliplatin, and Docetaxel versus Fluorouracil or Capecitabine plus Cisplatin and Epirubicin for Locally Advanced, Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma (FLOT4): A Randomised, Phase 2/3 Trial. The Lancet, 393, 1948-1957.
[24]
Ajani, J.A., D’Amico, T.A., Bentrem, D.J., Chao, J., Cooke, D., Corvera, C., et al. (2022) Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 20, 167-192.
[25]
Lordick, F., Carneiro, F., Cascinu, S., Fleitas, T., Haustermans, K., Piessen, G., et al. (2022) Gastric Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 33, 1005-1020. https://doi.org/10.1016/j.annonc.2022.07.004
[26]
Tsuburaya, A., Mizusawa, J., Tanaka, Y., Fukushima, N., Nashimoto, A., Sasako, M., et al. (2014) Neoadjuvant Chemotherapy with S-1 and Cisplatin Followed by D2 Gastrectomy with Para-Aortic Lymph Node Dissection for Gastric Cancer with Extensive Lymph Node Metastasis. British Journal of Surgery, 101, 653-660. https://doi.org/10.1002/bjs.9484
[27]
Ito, S., Sano, T., Mizusawa, J., Takahari, D., Katayama, H., Katai, H., et al. (2017) A Phase II Study of Preoperative Chemotherapy with Docetaxel, Cisplatin, and S-1 Followed by Gastrectomy with D2 plus Para-Aortic Lymph Node Dissection for Gastric Cancer with Extensive Lymph Node Metastasis: JCOG1002. Gastric Cancer, 20, 322-331. https://doi.org/10.1007/s10120-016-0619-z
[28]
Tokunaga, M., Mizusawa, J., Machida, N., Fukagawa, T., Katai, H., Nishida, Y., et al. (2017) Phase III Trial to Evaluate the Efcacy of Neoadjuvant Chemotherapy with S-1 plus Oxaliplatin Followed by D2 Gastrectomy with Adjuvant S-1 in Locally Advanced Gastric Cancer: Japan Clinical Oncology Group study JCOG1509 (NAGISA trial). Journal of Clinical Oncology, 35, TPS4134. https://doi.org/10.1200/JCO.2017.35.15_suppl.TPS4134
[29]
Kang, Y.K., Yook, J.H., Park, Y.K., Lee, J.S., Kim, Y.W., Kim, J.Y., et al. (2021) PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 plus Surgery and Adjuvant S-1 versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer. Journal of Clinical Oncology, 39, 2903-2913. https://doi.org/10.1200/JCO.20.02914
[30]
Sah, B.K., Zhang, B., Zhang, H., Li, J., Yuan. F., Ma, T., et al. (2020) Neoadjuvant FLOT versus SOX Phase II Randomized Clinical Trial for Patients with Locally Advanced Gastric Cancer. Nature Communications, 11, Article No. 6093. https://doi.org/10.1038/s41467-020-19965-6
[31]
Wang, F.H., Zhang, X.T., Li, Y.F., Tang, L., Qu, X.J., Ying, J.E., et al. (2021) The Chinese Society of Clinical Oncology (CSCO): Clinical Guidelines for the Diagnosis and Treatment of Gastric Cancer. Cancer Communications, 41, 747-795. https://doi.org/10.1002/cac2.12193
[32]
Guideline Committee of the Korean Gastric Cancer Association (2019) Development Working Group & Review Panel. Korean Practice Guideline for Gastric Cancer 2018: An Evidence-Based, Multi-Disciplinary Approach. Journal of Gastric Cancer, 19, 1-48. https://doi.org/10.5230/jgc.2019.19.e8
[33]
Harada, K., Kaya, M.D., Shimodaira, Y. and Ajani, J.A. (2017) Global Chemotherapy Development for Gastric Cancer. Gastric Cancer, 20, 92-101. https://doi.org/10.1007/s10120-016-0655-8
[34]
Zong, L., Abe, M., Seto, Y. and Ji, J. (2016) The Challenge of Screening for Early Gastric Cancer in China. The Lancet, 38, 2606 https://doi.org/10.1016/S0140-6736(16)32226-7
[35]
Thrift, A.P. (2021) Global Burden and Epidemiology of Barrett Oesophagus and Oesophageal Cancer. Nature Reviews Gastroenterology & Hepatology, 18, 432-443. https://doi.org/10.1038/s41575-021-00419-3
[36]
Yoshikawa, T., Morita, S., Tanabe, K., Nishikawa, K., Ito, Y., Matsui, T., et al. (2016) Survival Results of a Randomised Two-by-Two Factorial Phase II Trial Comparing Neoadjuvant Chemotherapy with Two and Four Courses of S-1 plus Cisplatin (SC) and Paclitaxel plus Cisplatin (PC) Followed by D2 Gastrectomy for Resectable Advanced Gastric Cancer. European Journal of Cancer, 62, 103-111. https://doi.org/10.1016/j.ejca.2016.04.012
[37]
Yoshikawa, T., Taguri, M., Sakuramoto, S., Kunisaki, C., Fukunaga, T., Ito, S., et al. (2012) A Comparison of Multimodality Treatment: Two and Four Courses of Neoadjuvant Chemotherapy Using S-1/CDDP or S-1/CDDP/Docetaxel Followed by Surgery and S-1 Adjuvant Chemotherapy for Macroscopically Resectable Serosa-Positive Gastric Cancer: A Randomized Phase II Trial (COMPASS-D Trial). Japanese Journal of Clinical Oncology, 42, 74-77. https://doi.org/10.1093/jjco/hyr166
[38]
Wang, X., Li, S., Sun, Y., Li, K., Shen, X., Xue, Y., et al. (2021) The Protocol of a Prospective, Multicenter, Randomized, Controlled Phase III Study Evaluating Different Cycles of Oxaliplatin Combined with S-1 (SOX) as Neoadjuvant Chemotherapy for Patients with Locally Advanced Gastric Cancer: RESONANCE-II Trial. BMC Cancer, 21, Article No. 20. https://doi.org/10.1186/s12885-020-07764-7
[39]
Kim, J.K., Marco, M.R., Roxburgh, C.S.D., Chen, C.T., Cercek, A., Strombom, P., et al. (2022) Survival after Induction Chemotherapy and Chemoradiation versus Chemoradiation and Adjuvant Chemotherapy for Locally Advanced Rectal Cancer. The Oncologist, 27, 380-388. https://doi.org/10.1093/oncolo/oyac025
[40]
Shi, J., Li, N., Tang, Y., Jiang, L., Yang, L., Wang, S., et al. (2022) Total Neoadjuvant Therapy for Locally Advanced Gastric Cancer and Esophagogastric Junction Adenocarcinoma: Study Protocol for a Prospective, Multicenter, Single-Arm, Phase II Clinical Trial. BMC Gastroenterology, 22, Article No. 359. https://doi.org/10.1186/s12876-022-02440-5
[41]
Bang, Y.J., Van Cutsem, E., Feyereislova, A., Chung, H.C., Shen, L., Sawaki, A., et al. (2010) Trastuzumab in Combination with Chemotherapy versus Chemotherapy Alone for Treatment of HER2-Positive Advanced Gastric or Gastro-Oesophageal Junction Cancer (ToGA): A Phase 3, Open-Label, Randomised Controlled Trial. The Lancet, 376, 687-697. https://doi.org/10.1016/S0140-6736(10)61121-X
[42]
Tokunaga, M., Machida, N., Mizusawa, J., Yabusaki, H., Yasui, H., Hirao, M., et al. (2022) A Randomized Phase II Trial of Preoperative Chemotherapy of S-1/CDDP with or without Trastuzumab Followed by Surgery in HER2 Positive Advanced Gastric or Esophagogastric Junction Adenocarcinoma with Extensive Lymph Node Metastasis: Japan Clinical Oncology Group study JCOG1301C (Trigger Study). Journal of Clinical Oncology, 40, 285 https://doi.org/10.1200/JCO.2022.40.4_suppl.285
[43]
Wagner, A.D., Grabsch, H.I., Mauer, M., Marreaud, S., Caballero, C., Thuss-Patience, P., et al. (2019) EORTC-1203-GITCG—The “INNOVATION”-Trial: Effect of Chemotherapy Alone versus Chemotherapy plus Trastuzumab, versus Chemotherapy plus Trastuzumab plus Pertuzumab, in the Perioperative Treatment of HER2 Positive, Gastric and Gastroesophageal Junction Adenocarcinoma on Pathologic Response Rate: A Randomized Phase II-Intergroup Trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer Group. BMC Cancer, 19, Article No. 494. https://doi.org/10.1186/s12885-019-5675-4
[44]
Cunningham, D., Stenning, S.P., Smyth, E.C., Okines, A.F., Allum, W.H., Rowley, S., et al. (2017) Peri-Operative Chemotherapy with or without Bevacizumab in Operable Oesophagogastric Adenocarcinoma (UK Medical Research Council ST03): Primary Analysis Results of a Multicentre, Open-Label, Randomised Phase 2-3 Trial. The Lancet Oncology, 18, 357-370. https://doi.org/10.1016/S1470-2045(17)30043-8
[45]
Zheng, Y., Yang, X., Yan, C., Feng, R., Sah, B.K., Yang, Z., et al. (2020) Effect of Apatinib plus Neoadjuvant Chemotherapy Followed by Resection on Pathologic Response in Patients with Locally Advanced Gastric Adenocarcinoma: A Single-Arm, Open-Label, Phase II Trial. European Journal of Cancer, 130, 12-19. https://doi.org/10.1016/j.ejca.2020.02.013
[46]
Lin, J., Xu, Y., Lin, W., Xue, F., Ye, J., Zang, W., et al. (2021) Effectiveness and Safety of Apatinib plus Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer: A Nonrandomized Controlled Trial. JAMA Network Open, 4, e2116240. https://doi.org/10.1001/jamanetworkopen.2021.16240
[47]
Tang, Z., Wang, Y., Yu, Y., Cui, Y., Liang, L., Xu, C., et al. (2022) Neoadjuvant Apatinib Combined with Oxaliplatin and Capecitabine in Patients with Locally Advanced Adenocarcinoma of Stomach or Gastroesophageal Junction: A Single-Arm, Open-Label, Phase 2 Trial. BMC Medicine, 20, Article No. 107. https://doi.org/10.1186/s12916-022-02309-0
[48]
Alsina, M., Arrazubi, V., Diez, M. and Tabernero, J. (2022) Current Developments in Gastric Cancer: From Molecular Profiling to Treatment Strategy. Nature Reviews Gastroenterology & Hepatology, 20, 155-170. https://doi.org/10.1038/s41575-022-00703-w
[49]
Bang, Y.J., Van Cutsem, E., Fuchs, C.S., Ohtsu, A., Tabernero, J., Ilson, D.H., et al. (2019) KEYNOTE-585: Phase III Study of Perioperative Chemotherapy with or without Pembrolizumab for Gastric Cancer. Future Oncology, 15, 943-952. https://doi.org/10.2217/fon-2018-0581
[50]
Al-Batran, S.E., Lorenzen, S., Thuss-Patience, P.C., Homann, N., Schenk, M., Lindig, U., et al. (2022) Surgical and Pathological Outcome, and Pathological Regression, in Patients Receiving Perioperative Atezolizumab in Combination with FLOT Chemotherapy versus FLOT Alone for Resectable Esophagogastric Adenocarcinoma: Interim Results from DANTE, a Randomized, Multicenter, Phase IIb Trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK. Journal of Clinical Oncology, 40, 4003-4003. https://doi.org/10.1200/JCO.2022.40.16_suppl.4003
[51]
Tao, K.X., Yin, Y.P., Lin, Y., Li, W., Li, R.D., Liu, W.Z., et al. (2022) Neoadjuvant PD-1 Inhibitor Tislelizumab Combined with S-1 plus Oxaliplatin in Patients with Local Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma: Interim Results of a Single-Arm, Phase II Trial. Journal of Clinical Oncology, 40, 300. https://doi.org/10.1200/JCO.2022.40.4_suppl.300
[52]
Chen, L., Ye, Z., Liu, G., Chi, Y., Wang, J., Wei, S., et al. (2022) 85P Tislelizumab Combined with Apatinib and Oxaliplatin plus S1 as Neoadjuvant Therapy for Borrmann IV Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer: A Single-Arm Multicenter Trial (TAOS-3B-Trial). Immuno-Oncology and Technology, 16, e100189. https://doi.org/10.1016/j.iotech.2022.100189
[53]
Bando, E., Makuuchi, R., Irino, T., Tanizawa, Y., Kawamura, T. and Terashima, M. (2019) Validation of the Prognostic Impact of the New Tumor-Node-Metastasis Clinical Staging in Patients with Gastric Cancer. Gastric Cancer, 22, 123-129. https://doi.org/10.1007/s10120-018-0799-9
[54]
Fukagawa, T., Katai, H., Mizusawa, J., Nakamura, K., Sano, T., Terashima, M., et al. (2018) A Prospective Multi-Institutional Validity Study to Evaluate the Accuracy of Clinical Diagnosis of Pathological Stage III Gastric Cancer (JCOG1302A). Gastric Cancer, 21, 68-73. https://doi.org/10.1007/s10120-017-0701-1
[55]
Iwasaki, Y., Sasako, M., Yamamoto, S., Nakamura, K., Sano, T., Katai, H., et al. (2013) Phase II Study of Preoperative Chemotherapy with S-1 and Cisplatin Followed by Gastrectomy for Clinically Resectable Type 4 and Large Type 3 Gastric Cancers (JCOG0210). Journal of Surgical Oncology, 107, 741-745. https://doi.org/10.1002/jso.23301
[56]
Terashima, M., Iwasaki, Y., Mizusawa, J., Katayama, H., Nakamura, K., Katai, H., et al. (2019) Randomized Phase III Trial of Gastrectomy with or without Neoadjuvant S-1 plus Cisplatin for Type 4 or Large Type 3 Gastric Cancer, the Short-Term Safety and Surgical Results: Japan Clinical Oncology Group Study (JCOG0501). Gastric Cancer, 22, 1044-1052. https://doi.org/10.1007/s10120-019-00941-z
[57]
Kataoka, K., Tokunaga, M., Mizusawa, J., Machida, N., Katayama, H., Shitara, K., et al. (2015) A Randomized Phase II Trial of Systemic Chemotherapy with and without Trastuzumab Followed by Surgery in HER2-Positive Advanced Gastric or Esophagogastric Junction Adenocarcinoma with Extensive Lymph Node Metastasis: Japan Clinical Oncology Group Study JCOG1301 (Trigger Study). Japanese Journal of Clinical Oncology, 45, 1082-1086. https://doi.org/10.1093/jjco/hyv134
[58]
Morita, S., Ito, S., Sano, T., Takahari, D., Katayama, H., Mizusawa, J., et al. (2019) Long-Term Outcome of Preoperative Docetaxel with Cisplatin plus S-1 Therapy for Advanced Gastric Cancer with Extensive Nodal Metastasis (JCOG1002). Journal of Clinical Oncology, 37, 141. https://doi.org/10.1200/JCO.2019.37.4_suppl.141
[59]
Cui, Y., Zhang, J., Li, Z., Wei, K., Lei, Y., Ren, J., Wu, L., Shi, Z., Meng, X., Yang, X. and Gao, X. (2022) A CT-Based Deep Learning Radiomics Nomogram for Predicting the Response to Neoadjuvant Chemotherapy in Patients with Locally Advanced Gastric Cancer: A Multicenter Cohort Study. EClinicalMedicine, 46, e101348. https://doi.org/10.1016/j.eclinm.2022.101348
